Repligen Corporation $RGEN Stock Holdings Boosted by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 10.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,057,975 shares of the biotechnology company’s stock after acquiring an additional 101,062 shares during the period. Repligen comprises approximately 2.9% of Conestoga Capital Advisors LLC’s holdings, making the stock its 10th biggest holding. Conestoga Capital Advisors LLC’s holdings in Repligen were worth $173,360,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new position in Repligen during the third quarter worth approximately $29,000. Bayforest Capital Ltd purchased a new position in Repligen during the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the fourth quarter worth approximately $33,000. CWM LLC raised its stake in Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

RGEN has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. Barclays dropped their price objective on shares of Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Finally, Wells Fargo & Company dropped their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $170.25.

Repligen Price Performance

Repligen stock opened at $118.31 on Friday. Repligen Corporation has a 52-week low of $109.50 and a 52-week high of $175.77. The firm has a fifty day moving average of $121.56 and a 200-day moving average of $144.73. The firm has a market capitalization of $6.67 billion, a P/E ratio of 139.19, a PEG ratio of 2.20 and a beta of 1.19. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. During the same quarter in the prior year, the business earned $0.44 earnings per share. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, analysts predict that Repligen Corporation will post 1.97 EPS for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.